『Cerebrovascular disease treatment, Alportin soft capsule launched』
KyungDong Pharm Co., Ltd. will release Alportin soft capsule, a treatment for cerebrovascular disease, on May 1.
Alpotin soft capsule is a precursor to acetylcholine and has a pharmacological mechanism that improves brain nerve transmission and regenerates damaged brain nerve cell membranes. It easily passes through the BBB (Blood Brain Barrier) and acts directly on damaged brain cells, showing excellent effects in improving cognitive abilities and behavioral disorders such as memory, language, and spatial perception.
In addition, Alportin soft capsules are a precursor to biomaterials, and because 85% of them are excreted as CO2, they have a very low side effect rate and excellent safety.
With the launch of Alportin soft capsules, we expect to see overall growth in KyungDong Pharm's brain function improvement product line along with the existing Neurocetyl tablets (Acetyl-l-carnitine 590 mg).
♠ Product Information ♠
|
Product name |
Alportin soft capsule |
|
Ingredient content |
Of 1 capsule Choline alfoscerate 400 mg |
|
Gender |
Light yellow, oval-shaped soft capsule containing a colorless and transparent viscous liquid. |
|
Indications |
Secondary symptoms due to cerebrovascular defects and degenerative or degenerative brain organic syndrome - Disorientation due to poor memory, confusion, and decreased motivation and spontaneity, Decreased motivation and spontaneity, decreased concentration - Emotional and behavioral changes: emotional anxiety, irritability, indifference to surroundings - Geriatric pseudodepression |
|
Dosage and usage |
Choline alfoscerate is administered orally at a dose of 400 mg 2-3 times a day. Increase or decrease appropriately depending on symptoms. |
|
How to save |
Airtight container, stored at room temperature (1~30℃) |
|
Packaging unit |
90 capsules |
|
Insurance claim code |
648103370 |
* For further details, please refer to the product manual.